The government is in the process of finalizing the 2021 Basic Policy for Economic and Fiscal Management and Reform (honebuto). This year’s policy will have a higher importance than previous ones because the drastic reforms of the drug pricing system…
ORGANIZATION
Teshirogi, Nakayama to Lead Japan Pharma Lobbies for 1 More Year; Ex-MHLW Official Shiraishi to Join JPMA
Japan’s two major pharma lobbies are retaining their chiefs for one more year to weather upcoming discussions to delineate the scope of so-called “off-year” re-pricing, which will begin in April 2021, people familiar with the matter told Jiho. Shionogi President…
To read the full story
Related Article
- Eisai’s Okada Elected as JPMA Chief, Daiichi Sankyo’s Manabe to Head FPMAJ
May 21, 2021
- Japan Pharma Lobbies Shifting to Manabe/Okada Leadership? Their Abilities Will Be Tested as Industry Grapples with Thorny Issues
January 7, 2021
- Ex-MHLW Councilor Mori to Become JPMA’s Sr. Managing Director in October
September 18, 2020
- JPMA to Commit to Growth of Research-Driven Pharma Industry, R&D of COVID-19 Drugs, Vaccines: Director General
September 7, 2020
- Daiichi Sankyo CEO Manabe Set to Gain Lobbying Experience as FPMAJ Vice Chair, Chairman Seat Eyed for 2021
June 10, 2020
- JPMA to Compile Proposal for Measures against Infectious Diseases: Chief
May 29, 2020
- Japan Pharma Lobbies Hammer Out One-Year Term Extensions for Their Leaders
March 24, 2020
- Japan Pharma Lobbies Likely to Retain Chiefs as Off-Year Re-Pricing Debate Looms
February 21, 2020
ORGANIZATION
- PhRMA Posts Its Position on Japan CEA Scheme on Website
June 11, 2021
- Eisai’s Akana Re-Elected as FPMAJ’s Drug Pricing Chief
June 11, 2021
- Terumo’s Mimura Elected New Medical Devices Chief; Reimbursement Debate Ahead for SaMD
June 9, 2021
- Experts Eye Macroeconomic Indexing of Drug Costs to Keep Innovation Afloat: INES Proposal
May 31, 2021
- Ken Suzuki Returns to JPWA Reins after 2 Years
May 28, 2021
Last month, when discussing how life science manufacturers should react to the evolving pricing environment in Japan, I wrote about how manufacturers should align with stakeholders in government and the medical community on fair compensation for innovative, value creating, biopharmaceutical…
The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…